Last reviewed · How we verify
Adjuvant Palbociclib in Elderly Patients With Breast Cancer (Appalaches)
Phase II study to assess the efficacy of the combination of at least 5 year endocrine therapy and 2 year-palbociclib as adjuvant systemic treatment instead of adjuvant chemotherapy followed by endocrine therapy in older patients with stage II-III ER+/HER2- early breast cancer.
Details
| Lead sponsor | European Organisation for Research and Treatment of Cancer - EORTC |
|---|---|
| Phase | PHASE2 |
| Status | ACTIVE_NOT_RECRUITING |
| Enrolment | 366 |
| Start date | Fri Jun 14 2019 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Thu Sep 30 2032 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Breast Cancer Stage II
- Breast Cancer Stage III
Interventions
- Palbociclib
- Docetaxel / cyclophosphamide
- doxorubicin/cyclophosphamide
- epirubicin/cyclophosphamide
- paclitaxel
Countries
France, Jordan, Italy, Belgium, United Kingdom, Germany, Poland, Portugal, Spain